Back to Search Start Over

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.

Authors :
Netto GJ
Amin MB
Compérat EM
Gill AJ
Hartmann A
Moch H
Menon S
Raspollini MR
Rubin MA
Srigley JR
Hoon Tan P
Tickoo SK
Tsuzuki T
Turajlic S
Cree I
Berney DM
Source :
European urology [Eur Urol] 2023 Apr; Vol. 83 (4), pp. 301-303. Date of Electronic Publication: 2022 Oct 04.
Publication Year :
2023

Abstract

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.<br /> (Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-7560
Volume :
83
Issue :
4
Database :
MEDLINE
Journal :
European urology
Publication Type :
Editorial & Opinion
Accession number :
36202687
Full Text :
https://doi.org/10.1016/j.eururo.2022.09.015